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Abstract
In rodent and human brains, the small GTP-binding protein Rhes is highly expressed in virtually
all dopaminoceptive striatal GABAergic medium spiny neurons, as well as in large aspiny cholin-
ergic interneurons, where it is thought to modulate dopamine-dependent signaling. Consistent
with this knowledge, and considering that dopaminergic neurotransmission is altered in neuro-
logical and psychiatric disorders, here we sought to investigate whether Rhes mRNA expres-
sion is altered in brain regions of patients with Parkinson’s disease (PD), Schizophrenia (SCZ),
and Bipolar Disorder (BD), when compared to healthy controls (about 200 post-mortem sam-
ples). Moreover, we performed the same analysis in the putamen of non-human primate
Macaca Mulatta, lesioned with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP). Overall, our data indicated comparable Rhes mRNA levels in the brain of patients with
SCZ and BD, and their respective healthy controls. In sharp contrast, the putamen of patients
suffering from PD showed a significant 35% reduction of this transcript, compared to healthy
subjects. Interestingly, in line with observations obtained in humans, we found 27% decrease in
Rhes mRNA levels in the putamen of MPTP-treated primates. Based on the established inhibi-
tory influence of Rhes on dopamine-related responses, we hypothesize that its striatal downre-
gulation in PD patients and animal models of PD might represent an adaptive event of the
dopaminergic system to functionally counteract the reduced nigrostriatal innervation.
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Introduction
Rhes (RASD2) is a gene encoding for a GTP-binding protein highly enriched in the corpus stria-
tum [1–3], and developmentally regulated by thyroid hormones [4, 5]. To a lesser extent, also
dopamine regulates Rhes mRNA levels in adult rat striatum [6, 7]. Neuroanatomical observa-
tions, performed on human and rodent brains, showed that Rhes mRNA is localized in virtually
all dopamine D1 and D2 receptor (R)-bearing medium-sized spiny neurons, as well as in cholin-
ergic interneurons of the caudate-putamen [8–10]. Rhes transcript is also expressed in rodent
and human hippocampus, within the granule cell layer of the dentate gyrus and pyramidal cell
layer of Ammon’s horn [1, 2, 7, 8, 11]. Interestingly, in mice Rhes mRNA-positive neurons are
distributed within the cortical layers II-III, while in the human cortex Rhes transcript is detected
throughout layers II–VI, with a distinctive higher expression in layer V [12]. From a functional
perspective, Rhes modulates striatal dopamine D1R and D2R transmission, by influencing
cAMP/PKA and AKT pathways [8–11, 13–16]. Rhes also binds to and activates mTORC1 signal-
ling in the striatum, which is known to influence the expression of L-DOPA-induced dyskinesia
(LID) in rodent PD models [17, 18]. Accordingly, we recently found that dopamine-depleted
Rhes knockout mice show a significant LID reduction, while the beneficial anti-akinetic effect of
L-DOPA is preserved [19, 20]. Strikingly, Snyder and colleagues reported that Rhes acts as a
unique striatal E3 ligase for mutant huntingtin sumoylation, a biochemical process that causes
cellular neurotoxicity in Huntington’s disease [21–26]. Thus, in addition to its involvement in
PD-related processes, Rhes is currently considered to be a molecular determinant in cellular and
behavioural Huntington’s disease-associated phenotypes [27]. Though a putative link between
Rhes and neurodegenerative disorders has been established, this G-protein, by regulating AKT
and cAMP/PKA signalling, might also play a role in biochemical pathways in the brain of BD
and SCZ patients [28–30]. Accordingly, a variant of the Rhes gene (rs736212) has been associated
with a sub-group of patients with SCZ [31], while another polymorphism (rs6518956) relevant
for SCZ correlates with fronto-striatal endophenotypes in healthy subjects [12]. Consistent with
its potential role in psychiatric diseases, Rhes also interacts with striatal proteins, such as PDE2A
(phosphodiesterase 2A) and LRRC7 (leucine-rich repeat–containing 7), reported to be associated
with major depression and BD [32]. Therefore, in order to investigate the possible alteration of
Rhes mRNA expression in neurodegenerative and psychiatric disorders, we evaluated whether
its transcript levels might be affected by the diagnosis of PD, SCZ and BD. To further dissect
whether Rhes gene expression might be influenced by the dopamine denervation in an experi-
mental non-human primate model of PD, we also evaluated striatal levels of Rhes mRNA in
Macaca Mulatta, treated with MPTP.
Materials and methods
All human tissue collection and processing was carried out in accordance with the declaration
of Helsinki. In Italy there is no law regulating the use of biological samples obtained from
internationally recognized brain banks. Therefore, because our study did not involve pharma-
cological research, which is regulated in Italy, ethics committee approval was not required.
Non-human primate studies were carried out in accordance with European Communities
Council Directive (2010/63/EU) for care of laboratory animals in an AAALAC-accredited
facility following acceptance of study design by the Institute of Lab Animal Science IACUC
(Chinese Academy of Medical Sciences, Beijing, China).
Human tissue collection
Putamen samples of normal controls and PD patients were obtained from the Harvard Brain
Tissue Resource Center (HBTRC; http://www.brainbank.mclean.org/). The clinical and
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neuropathological criteria for a diagnosis of PD are summarized in Table 1. Dorsolateral
prefrontal cortex and hippocampus samples of patients with SCZ and non-psychiatric con-
trols were obtained from The Human Brain and Spinal Fluid Resource Center-Los Angeles
(HBSFRC). Prefrontal cortex and putamen samples of patients with SCZ and non-psychiat-
ric controls were obtained from MRC London Neurodegenerative Diseases Brain Bank
(MRC-LNDBB). Anterior cingulate cortex samples of patients with SCZ, BD, and non-psy-
chiatric controls, were donated by The Stanley Medical Research Institute (SMRI) brain col-
lection. SCZ and BD diagnoses were established according to DSM IV criteria (see Table 2).
For more information about medication of psychiatric patients see S1 and S2 Tables. All
human data were anonymized.
Non-human primates housing
Captive bred female macaques (Macaca mulatta, Xierxin, Beijing, PR of China; mean
age = 5 ± 1 years; mean weight = 5.3 ± 0.8 kg), were housed in individual primate cages under
controlled conditions of humidity (50 ± 5%), temperature (24 ± 1˚C), and light (12 h light/12
h dark cycles, time lights on 8:00 am), and allowing visual contacts and interaction with
macaques housed in the adjacent cages. Food and water were available ad libitum and animal
care was supervised daily by veterinarians skilled in the healthcare and maintenance of non-
human primates.
MPTP-treated non-human primate PD model
Out of fifteen macaques, five received daily MPTP hydrochloride injections (0.2mg/kg, intra-
venously) until parkinsonian signs appeared [33]. Once PD motor signs were stable, five more
animals were treated twice daily with an individually titrated dose of L-DOPA that provided
maximum reversal of parkinsonian motor signs (Madopar, L-DOPA/carbidopa, 4:1 ratio;
range, 9–17mg/kg). This dose of L-DOPA, defined as 100% dose, was used for chronic
L-DOPA treatment, which lasted 4 to 5 months until dyskinesia stabilized. Animals then
received L-DOPA twice a week to maintain a consistent level of dyskinesia before acute drug
tests were carried out using a within-subject experimental design. The remaining five monkeys
were used as control. Killing of animals and processing of tissues were carried out according to
a previous protocol [33]. Briefly, all the animals were killed by sodium pentobarbital overdose
(150 mg/kg, i.v.), and the brains were quickly removed after death. Each brain was bisected
along the midline, and the two hemispheres were immediately frozen by immersion in isopen-
tane (-45˚C) and then stored at -80˚C. Tissue was sectioned coronally at 20 μm in a cryostat at
-17˚C, thaw-mounted onto gelatin-subbed slides, dried on a slide warmer, and stored at
-80˚C.
In situ hybridization (ISH)
ISH analysis was performed on coronal sections from adult macaque brains (n = 3 control
group), according to a protocol previously described [12]. RASD2 cDNA was cloned by PCR
using the following primers: forward 5’-TACCAGCTGGACATCCTGG-3’, reverse 5’-
CGTCACCGTACTGCACGG-3’.RASD2 35S-labelled antisense riboprobe, 433 bp in length
(nucleotides 398–830, XM-015150119), was used ISH analysis. Hybridized sections were
exposed to Biomax MR X-ray films (Kodak, Rochester, NY) for three days. Images of autoradi-
ography films of radioactive ISH experiments were scanned at a resolution of 4800 dpi and
images at high magnification were acquired using bright field light microscopy [34].
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Table 1. Demographic table of PD brain samples from the Harvard Tissue Resource Center.
ID Diagnostic
group
Age
(years)
PMI
(hours)
Accumulated
lifetime L-dopa
(g)
Treatment
duration (y)
Average L-
dopa per
year treated
(g)
Years
diagnosed
Neurofibrillary
degeneration
(Braak Stage)
Cause of death
1 NC 70 14.3 myocardial
infarction
2 NC 71 14.07 Unknown
3 NC 72 21.62 myocardial
infarction
4 NC 72 18.25 cardiac Ischemia
5 NC 73 19.42 chronic obstructive
pulmonary disease
6 NC 73 12 Cancer
7 NC 73 7.58 cardiac Arrest
8 NC 74 22.5 chronic obstructive
pulmonary disease
9 NC 74 14.33 myocardial
infarction
10 NC 74 18.58 myocardial
infarction
11 NC 76 21.25 cardiopulmonary
arrest
12 NC 77 25.23 myocardial
infarction
13 NC 79 20.5 chronic obstructive
pulmonary disease
14 NC 79 20.81 motor vehicle
accident
15 NC 82 14.33 liver cancer
n = 15
(mean
±SEM)
74.87±0.804 17.94
±1.194
16 DYS 64 11.4 1,971 11 179 11 4 cardiopulmonary
arrest
17 DYS 71 5 128 1 128 8 1 cardiopulmonary
arrest
18 DYS 73 18 1,074 4 234 14 2 cardiopulmonary
arrest
19 DYS 75 13.3 1,752 8 219 11 1 cardiopulmonary
arrest
20 DYS 77 20.7 4,663 18 267 21 3 bladder cancer
21 DYS 78 14.5 2,197 9 233 11 2 pneumonia
22 DYS 79 23.4 1,476 8 197 8 3 cardiopulmonary
arrest
23 DYS 81 10.5 1,026 8 131 13 3 cardiopulmonary
arrest
24 DYS 87 11.7 2,373 13 183 13 3 cardiopulmonary
arrest
25 DYS 88 26.5 1,835 5 361 10 3 anoxic
encephalopathy
n = 10
(mean
±SEM)
77.3±2.3 15.5
±2.1
1,850
±375.9
8.5±1.5 213.2±21.6 12±1.2 2.5±0.3
26 Non-DYS 71 24.7 3,011 11 274 11 1 pneumonia
(Continued )
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Quantitative RT-PCR analysis in human post mortem brain samples and
macaques
Total RNAs from the HBSFRC, MRC-LNDBB, and SMRI brain samples were extracted using
RNeasy1 Mini kit (Quiagen, Hilden, Germany), according to the manufacturer’s instructions.
We used 0.5 μg of total RNA per sample to synthesize cDNA. Quantitative RT-PCR with Real
Time ready catalog Assays (hRhes forward: GGGAGCCACCACAGACTCand hRhes reverse:
CTGGACAAAGTCTTCATCATGG; GAPDH forward: AGCCACATCGCTCAGACAC and GAPDH
reverse: GCCCAATACGACCAAATCC; ACTB forward: TCCTCCCTGGAGAAGAGCTAand ACTB
reverse: CGTGGATGCCACAGGACT; PPIA forward: TTCATCTGCACTGCCAAGAC and PPIA
reverse: CACTTTGCCAAACACCACAT) and LightCycler1 480 Probe Master (Roche Diagnostics,
Indianapolis, IN) was performed on a Light Cycler 480 II Real Time PCR system with 96-well
format (Roche Diagnostics). All measurements from each subject were performed in duplicate.
Rhes transcript quantities were normalized by the geometric mean of three housekeeping genes
for analysing samples from MRC-LNDBB and SMRI (ACTB, GAPDH and PPIA), and two for
the samples of the HBSFRC (ACTB and PPIA). After total RNA extraction (0.5 μg) from
macaque tissue, quantitative Real Time amplifications were performed with LightCycler 480
Table 1. (Continued)
ID Diagnostic
group
Age
(years)
PMI
(hours)
Accumulated
lifetime L-dopa
(g)
Treatment
duration (y)
Average L-
dopa per
year treated
(g)
Years
diagnosed
Neurofibrillary
degeneration
(Braak Stage)
Cause of death
27 Non-DYS 75 14.1 1,232 5 235 12 2 PD
28 Non-DYS 75 20 511 4 120 5 2 liver cancer
29 Non-DYS 75 5.5 905 6 156 6 2 bladder cancer
30 Non-DYS 75 19.8 584 4 146 7 2 pneumonia
31 Non-DYS 75 16.5 548 4 137 12 3 colon cancer
32 Non-DYS 75 17.2 219 2 110 5 2 congestive heart
failure
33 Non-DYS 77 15.2 584 5 117 5 1 bradycardia, heart
blockage
34 Non-DYS 77 7.2 143 1 101 5 2 bladder cancer
35 Non-DYS 79 8.2 892 6 150 17 2 cardiopulmonary
arrest
36 Non-DYS 80 20.4 2,473 8 297 11 4 cardiopulmonary
arrest, pneumonia
37 Non-DYS 84 19.9 24 0 146 9 4 myocardial
infarction
n = 12
(mean
±SEM)
76.5±0.9 15.7
±1.7
927.2
±265.6
4.7±0.9 165.8±19 8.7±1.1 2.2±0.3
NC vs PD
(DYS
+Non-
DYS) (p
value)
0.0672 0.2494
DYS vs
Non- DYS
(p value)
0.6566 0.8718 0.0408 0.0391 0.1187 0.0642 0.4063
Abbreviations: NC, non-PD control; DYS, dyskinetic PD; Non-DYS, non-dyskinetic PD; PMI, post-mortem interval; Mann-Whitney U test for DYS vs non-
DYS characteristics
https://doi.org/10.1371/journal.pone.0181677.t001
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SYBR Green I Master (Roche Diagnostic), in a LightCycler 480 Real Time thermocycler
(Roche). The following protocol was used: 10 s for initial denaturation at 95˚C followed by 45
cycles consisting of 10 s at 94˚C for denaturation, 10 s at 65˚C for annealing, and 6 s for elonga-
tion at 72˚C temperature. The following primers were used for Rhes cDNA amplification:
MmRhes forward: TAACCGGGAGTCCTTCGATG and MmRhes reverse: CCTCAAAGTAGGCG
CAGTTC; Mmb-Actb forward: CTGTGCTATGTCGCCCTAGA and Mmb-Actb reverse: GGAAGG
TTGGAAGAGAGCCT. Rhes transcript quantities were normalized by the geometric mean of
three housekeeping genes [12, 35, 36]: MmPp1a forward: TGCTGGACCCAACACAAATG and
MmPp1a reverse: GTCCACAGTCAGCAATGGTG;MmGAPDH forward: AGGTCGGAGTCAACG
GATTT and MmGAPDH reverse: ATCTCGCTCCTGGAAGATGG. Total RNA (150 ng) was
extracted from the Putamen of HBTRC samples using the RNeasy Mini Kit (Qiagen). DNA was
eliminated from the sample by treatment with DNase I (New England Biolabs, Ipswich, MA).
cDNA was synthesized from 150 ng RNA with the Superscript IV kit and random hexamers
(Thermo Fisher Scientific, Waltham, MA). Quantitative Real Time PCR amplifications were per-
formed with KAPA SYBR Fast, with ROX as a loading control (Roche Diagnostics), in the
MX3005P thermocycler (Agilent Technologies, Wilmington, DE), under the following cycle
conditions: 10 min at 95˚C for initial denaturation followed by 40 cycles of 20 s at 95˚C for
Table 2. Demographic table of psychiatric brain samples.
The Human Brain and Spinal Fluid Resource Center (Los Angeles, CA)
NC group SCZ group p value
n = 20 (median; sum of ranks) n = 20 (median; sum of ranks)
Age 73.5; 555 52.5; 265 < 0.0001
PMI (h) 12.85; 335 15.25; 485 0.0422
pH 6.545; 223.5 6.5; 182.5 0.3574
Gender 16 M, 4 F 12M, 8 F χ2 = 1.905 0.1675
Diagnosis DSMIV-TR
MRC London Neurodegenerative Diseases Brain Bank
NC group SCZ group p value
n = 12 (median; sum of ranks) n = 10 (median; sum of ranks)
Age 63.5;140.5 63; 112.5 0.8836
PMI (h) 31.5; 95 48; 136 0.0070
Gender 6M, 6F 6M, 4F χ2 = 0.2200 0.6390
Diagnosis DSMIV-TR
The Stanley Medical Research Institute
NC group SCZ group BD group p value
n = 32 (median;sum of ranks) n = 36 (median;sum of ranks) n = 29 (median;sum of raks)
Age 44.5; 1109 43.5; 12.38 NC vs SCZ 0.9586
44.5; 963 44; 928 NC vs BD 0.6799
PMI (h) 28; 1059 30; 1288 NC vs SCZ 0.5803
28; 862.5 35; 1029 NC vs BD 0.0614
Gender 23M, 9F 27M, 9F 14M, 15F χ2 0.0850 0.7706
(NC vs SCZ)
χ2 3.550 09.55.00
(NC vs BD)
Diagnosis DSMIV-TR
Abbreviations: NC, non-psychiatric control; SCZ, schizophrenia; BD, bipolar disorder; PMI, postmortem interval; h, hours; M/F, male/female; Mann-Whitney
U test for Age and PMI characteristics. Chi-square test for Gender characteristic. DMS, Diagnostic and Statistical Manual of mental disorders
https://doi.org/10.1371/journal.pone.0181677.t002
Striatal Rhes mRNA downregulation in patients with Parkinson’s disease and MPTP-treated macaques
PLOS ONE | https://doi.org/10.1371/journal.pone.0181677 July 25, 2017 6 / 15
denaturation, 20 s at 60˚C for annealing, and 20 s at 74˚C for elongation. The following primers
were used for Rhes cDNA amplification: hRHES-F: TCCATCGTGTCTCGCTTCCT and hRHES-
R: CTCATCGAAGGACTCCCGGT. Rhes transcript quantities were normalized by the geometric
mean of five housekeeping genes [12, 35, 36]: Human 18s rRNA-F: ACGGCCGGGGGCATTCG
TAT, Human 18s rRNA-R: ATCGCCGGTCGGCATCGTTT; hITM2B-F: CATTGTTATGCCACC
CAGAA, hITM2B-R: GCAGTTTGTAAGTTTCCTTGTCA; hCANX-F: ACTTGTGTTGATGTCT
CGGGC, hCANX-R: CGTTTTGGGGTTTTTGTGTCGG; hActb-F: AGAGCCTCGCCTTTGCC
GATCC, hActb-R: CATGCCGGAGCCGTTGTCGAC; hEIF1-F: GTGATGACCTGCTTCCTGCT,
hEIF1-R: CTTGCGTTGGTCACCCTGTA.
Data were analysed through Kruskal-Wallis test and/or Mann-Whitney U test, by using
GraphPad software (La Jolla, CA).
Results
Expression levels of Rhes mRNA in Parkinson’s disease, Schizophrenia
and Bipolar Disorder human brains
We analysed Rhes mRNA levels, by qPCR analysis, in different cerebral regions of
patients affected by PD, SCZ and BD (See Tables 1 and 2 for demographic details),
obtained from four different human brain banks. Notably, our data showed a significant
decrease in Rhes mRNA amount in the putamen of PD patients from the HBTRC, com-
pared to the control group (P = 0.0420; Mann-Whitney U test; Fig 1A). Since PD group
consists of dyskinetic and non-dyskinetic patients, we also compared Rhes mRNA levels
among these groups. Overall, Kruskal-Wallis analysis revealed a clear trend toward red-
uction of Rhes expression in both dyskinetic and non-dyskinetic patients, compared to
controls (P = 0.0634; Fig 1B).
Conversely, comparable levels of Rhes mRNA were found between SCZ patients and
healthy controls, in both dorsolateral prefrontal cortex (P = 0.6783; Mann-Whitney U test; Fig
1C) and hippocampus (P = 0.7632; Fig 1D) samples from the HBSFRC. Similar results were
also obtained in both prefrontal cortex (P = 0.4611; Mann-Whitney U test; Fig 1E) and puta-
men of SCZ patients (P = 0.5254; Fig 1F) from the MRC-LNDBB. In addition, qPCR analysis
in the anterior cingulate cortex of SCZ brains from the SMRI, displayed no difference in Rhes
mRNA levels, when compared to non-psychiatric controls (P = 0.9246; Mann-Whitney U test;
Fig 1G). Finally, analysis of mRNA levels in the same brain region of patients with BD,
obtained from the SMRI, revealed no difference when compared to non-psychiatric controls
(P = 0.2254; Fig 1H).
Localization of Rhes mRNA in macaque brain
To identify the spatial pattern of Rhes mRNA expression we performed in situ hybridization
analysis on coronal sections of frozen brains of adult non-human primates, Macaca Mulatta.
In agreement with previous reports in rodent and human brains [8, 9, 12], abundant levels of
Rhes mRNA were observed in the striatum of macaques (Fig 2B and 2C; corresponding brain
atlas tables are depicted in A and C, respectively). An enriched amount of Rhes transcript was
evident along the rostro-caudal extent of the striatum in the caudate nucleus and putamen (Fig
2B”, 2B”‘, 2D’ and 2D”). In addition, consistent with previous observations in human brains
[8], Rhes mRNA was also expressed in the deep layers of the cerebral cortex (Fig 2B”‘ and
2D”), Cornu Ammonis (CAM) and in the dentate gyrus (DG) of the Macaca Mulatta brain (Fig
2D”‘).
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Fig 1. Quantitative RT-PCR analysis shows a selective reduction in Rhes mRNA levels in post-
mortem brain samples of patients with Parkinson’s disease. (A) Putamen samples of PD patients
Striatal Rhes mRNA downregulation in patients with Parkinson’s disease and MPTP-treated macaques
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Rhes mRNA expression levels in the brain of MPTP-treated Macaca
Mulatta
After establishing its brain localization in healthy macaques, we analysed the amount of Rhes
mRNA in the putamen of monkeys treated with MPTP (Fig 3A), highly regarded as an experi-
mental model of PD [37]. Remarkably, Kruskal-Wallis analysis displayed a significant variation
of Rhes transcript levels among control vs MPTP vs MPTP+L-DOPA putamen (P = 0.0176; Fig
3B). In particular, Mann-Whitney test showed a significant downregulation of Rhes mRNA
(n = 22), and non-PD controls (n = 15), from the HBTRC. (B) Putamen samples of non-dyskinetic (n = 12) and
dyskinetic (n = 10) patients and non-PD controls, from the HBTRC. (C, D) Dorsolateral prefrontal cortex (C)
and hippocampus (D) samples from patients with SCZ (n = 20) and non-psychiatric controls (n = 20), from the
HBSFRC. (E) Prefrontal cortex samples of patients with SCZ (n = 16) and non-psychiatric controls (n = 19),
from MRC-LNDBB. (F) Putamen samples of patients with SCZ (n = 12) and non-psychiatric controls (n = 11),
from MRC-LNDBB. (G, H) Anterior cingulate cortex samples of patients with SCZ (n = 36) (G), BD (n = 29) (H)
and non-psychiatric controls (n = 32), from the SMRI. Data were analysed by using Kruskal-Wallis test or
Mann-Whitney U test. * p<0.05, compared to non-pathological control (NC) group. All values are expressed
as mean ± SEM.
https://doi.org/10.1371/journal.pone.0181677.g001
Fig 2. Rhes mRNA expression in Macaca mulatta adult brain. (A, C) Graphic representation of Macaca
mulatta brain sections examined. Rostro-caudal levels are approximate and sections were obtained from
www.brainmaps.org [34]. (B, D) Representative images of autoradiographic film of radioactive ISH
experiments showing Rhes expression along the rostro-caudal extent of Macaca mulatta adult brain. Boxed
regions in B and D are shown at higher magnification in (B’) cortical area 6 of the brain, (D’) cortical area 3 of
the brain, (B”- B”‘, D’-D”) caudate nucleus and putamen of striatum, (D”‘) cornus Ammoni and dentate gyrus of
hippocampus. Abbreviations: 3: cortical area 3; 6: cortical area 6; CA: caudate nucleus; CAM: Cornus
Ammonis; CC: corpus callosum; CL: central lateral nucleus of the thalamus; DG: dentate gyrus; ENT:
entorhinal cortex; GP: globus pallidus; IC: internal capsule; Ins: insula; LS: lateral sulcus; PCS: precentral
sulcus; PSB: presubiculum; Pu: putamen; R: reticular nucleus; OT: optic tract; SB: subiculum. Scale bar: 5
mm (A-B, C-D); 1.75 mm (B’-B”‘, D’-D”‘).
https://doi.org/10.1371/journal.pone.0181677.g002
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amount in MPTP-treated monkeys (control vs MPTP: P = 0.0079), that was normalized after
2-week L-DOPA supplementation (control vs MPTP+L-DOPA: P = 0.3095).
Discussion
Despite an emerging interest in Rhes as a novel molecular target in striatal neuropathology,
the vast majority of studies so far were performed in cell cultures and rodent models [16].
Here, we measured Rhes mRNA levels in a large group of post-mortem samples (about 200),
from subjects diagnosed with SCZ, BD, PD or healthy controls, obtained from four different
international brain banks. Altogether, our results indicated that Rhes mRNA levels in the puta-
men, hippocampus, anterior cingulate cortex, frontal and dorsolateral prefrontal cortex of
SCZ patients did not significantly differ from those of healthy subjects. Similarly, in the ante-
rior cingulate cortex of individuals suffering from BD, Rhes mRNA expression was compara-
ble to that of non-psychiatric subjects. The lack of significant differences in Rhes mRNA
expression between brain samples from controls and psychiatric patients does not rule out a
possible influence of previous pharmacological medications. However, preclinical data in rats
showed that chronic treatment with eticlopride, a selective D2R blocker, did not alter the stria-
tal expression of this gene [6].
In contrast with the findings obtained in SCZ and BD brains, we found a significant reduc-
tion of Rhes transcript levels in the post-mortem putamen of PD patients. It’s worth mention-
ing that both age and PMI values are comparable between healthy controls and PD patients
(NC vs PD: Age, P = 0.0672; PMI, P = 0.2494, Mann-Whitney U test; for further details, see
Table 1), thus suggesting that such a downregulation is most likely associated to the pathologi-
cal condition, rather than demographic sample features. On the other hand, in line with
Fig 3. Quantitative RT-PCR analysis shows a selective reduction of Rhes mRNA levels in the MPTP macaque PD
model, recovered by L-DOPA treatment. (A) Experimental design. (B) Putamen of MPTP (n = 5), MPTP+L-DOPA (n = 5)
or control (n = 5) monkey groups. Data were analysed by using the Kruskal-Wallis test, followed by Mann-Whitney U test **
p<0.01, compared to control group. All values are expressed as mean ± SEM.
https://doi.org/10.1371/journal.pone.0181677.g003
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previous findings [38], dyskinetic patients analysed here showed a longer accumulated lifetime
L-DOPA (P = 0.0408) and duration of L-DOPA treatment (P = 0.0391), compared to non-dys-
kinetic subjects (Table 1).
Consistent with PD patient observations, a similar Rhes mRNA decrease was found also in
the putamen of MPTP-treated Macaca Mulatta. The overall downregulation of Rhes mRNA
levels in the putamen of both patients and the non-human primate model is in agreement with
previous findings obtained in the striatum of adult 6-OHDA-lesioned rats [6], suggesting that
the regulation of Rhes gene expression by dopaminergic innervation is conserved across spe-
cies. Although the biological role of this regulation is still unknown, the inhibitory influence of
Rhes over the striatal dopamine-dependent responses, documented by in vitro and in vivo
studies [9, 10, 15], let us hypothesize that the decrease of this G-protein may represent an
event, up-stream to a complex compensatory process, able to functionally counteract the path-
ological reduction of dopaminergic innervation. In this view, Rhes could act as a physiological
“molecular brake” for the striatal dopaminergic transmission, an idea also supported by the
evidence that the lack of this GTPase triggers exaggerated motor responses in Rhes knockout
mice, treated with very low doses of the dopamine releaser amphetamine [12].
In PD mouse model Rhes enhances L-DOPA-induced dyskinesia (LID), most likely
through the activation of mTOR pathway [20]. Accordingly, a significant LID reduction has
been observed in 6-OHDA-treated Rhes knockout mice [19, 20]. Here, despite the above pre-
clinical observations, we did not find any significant differences in the striatal Rhes mRNA lev-
els between dyskinetic and non-dyskinetic patients. Further studies on a larger cohort of post-
mortem brains from PD patients with, or without, dyskinesia, are required to clarify this issue.
Notably, we report that the pattern of Rhes mRNA expression in the brain of non-human
primates resembles that previously described in humans [8, 12]. Indeed, our observations in
adult Macaca Mulatta demonstrate a prominent expression of Rhes transcript in the caudate
putamen and, to a lesser extent, in the cortex, with a spatial pattern reminiscent to that in
human brain [12]. Interestingly, while L-DOPA administration to MPTP-treated monkeys
normalized striatal Rhes mRNA levels, this effect was not found in L-DOPA-treated PD
patients. This discrepancy might be explained by a difference in dopamine levels between PD
patients and MPTP-lesioned primates at the time of death or sacrifice, respectively. Indeed,
while MPTP-treated macaques were killed 60 min after L-DOPA injection [39], the last dose
of L-DOPA before death of PD patients was likely further in the past, and might have worn off.
However, whether or not the reported reduction of striatal Rhes mRNA expression in PD
patients and MPTP-treated macaques might also reflect a decreased expression of the corre-
sponding protein remains an issue to be addressed in future studies. In this respect, it has been
shown that mRNA expression is well correlated with protein levels [40], though differentially
expressed and highly expressed mRNAs correlate better with their protein product than non-
differentially expressed mRNAs [41]. This is not surprising, since low expressed mRNAs
and proteins have a higher degree of natural and methodological noise [42]. Rhes is highly
expressed in the putamen which indicates that differences in mRNA will likely be reflected in
protein levels. Furthermore, correlations of mRNA and protein in the PD putamen were previ-
ously verified for molecules such as alpha-synuclein and adenosine A2A receptors [43, 44].
A further support for a possible link between Rhes and Parkinson’s disease comes from
recent findings indicating that this small GTPase is also expressed in a subset of tyrosine
hydroxylase-positive neurons of the substantia nigra pars compacta, where its genetic ablation
enhances vulnerability to age-dependent neuronal death in mutant mice [45]. Although the
specific mechanism underpinning the relationship between Rhes and the survival of dopami-
nergic neurons is not clear, previous studies demonstrating its binding to beclin-1 [46] suggest
a potential involvement of this G protein in cellular events implicated in neurodegeneration.
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In conclusion, the present data obtained in both PD patients and experimental non-human
primate model of PD suggest that the regulation of Rhes mRNA levels by dopaminergic inner-
vation might play a functional role under physiological and pathological conditions.
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